ANYCOLOR <5032>: 2478 yen (+149 yen)

Significant continued rise. Announced the earnings reports for the first half on the previous day, with an operating profit of 6.76 billion yen, an increase of 4.3% year-on-year. Although this was below the previous financial estimates of 7.1 billion yen, it marks a recovery from the first quarter figure of 2.72 billion yen, a decrease of 32.8%. For the August to October period, a notable increase of 65.8% is expected. Considering the expansion of commerce and events, the expected operating profit for the November to January period is forecasted in the range of 3.45 to 3.75 billion yen, which corresponds to an increase of 34.8 to 46.6% compared to the same period last year.

Cell Source <4880>: 1070 yen (+48 yen)

Significant rebound. Announced an agreement on collaboration with NTT Docomo aimed at expanding awareness of regenerative medicine and others. It will share information regarding treatments using regenerative medicine through Docomo's health management and enhancement app for smartphones, "d Health Care." An expansion in customer approaches is anticipated. Additionally, an agreement was announced for cooperation in medical fitness aimed at extending healthy life years with Japan Post.

gumi <3903>: 435 yen (+47 yen)

Significant continued rise. Announced the earnings reports for the first half on the previous day, with an operating profit of 0.18 billion yen, improving by 2.15 billion yen year-on-year. The August to October period is expected to show a similar improvement of 1.44 billion yen. The benefits from the improvement of the revenue structure implemented in the first quarter and contributions from OSHI tokens seem to have increased the profit margin. Additionally, due to the recording of unrealized gains from cryptos, the recurring profit for the first half was 0.99 billion yen, reflecting an improvement of 3.12 billion yen.

Synchro Food <3963>: 361 yen (-56 yen)

Significant continued decline. Announced the implementation of a public offering of 2 million shares, a sale of 6 million shares, and an over allotment sale of up to 1.2 million shares. The number of offered shares is at a level of 7.4% of the issued shares. The estimated proceeds from the public offering are around 0.75 billion yen, which will be allocated for working capital and research and development funds for new business expansion. Meanwhile, the seller is Mr. Fujishiro, the representative director, and it seems the purpose is to meet the listing maintenance criteria in terms of the market cap of circulating shares.

Kurazushi <2695>: 3265 yen (-600 yen)

Significant decline. Announced the earnings report for the fiscal year ending October 2024, with operating profit reaching 5.7 billion yen, which is 2.3 times that of the previous year, slightly surpassing the previous estimate of 5.5 billion yen. The annual dividend was raised from the originally planned 20 yen to 40 yen, including a commemorative dividend of 20 yen. Meanwhile, for the fiscal year ending October 2025, operating profit is expected to be 5 billion yen, marking a 12.3% decrease, with the annual dividend set at 20 yen, excluding the commemorative dividend. Additionally, the announcement of the discontinuation of the shareholder benefit system that provided discount vouchers seems to have contributed to a negative impact.

Sasumedo <4263>: 585 yen (-5 yen)

Initial buying was gradually erased, leading to consolidation. The integrated venous disease registry system construction work, based on the basic agreement concluded with Tohoku Universities, has been completed, and provision to businesses has started. This registry can simultaneously collect information from patients using multiple medical devices such as new venous stents for symptomatic iliac-femoral venous outflow obstructions and new thrombus removal catheters for acute deep vein thrombosis. By sharing the collected data with relevant academic societies and manufacturers, it will be used in the creation of appropriate use guidelines issued by relevant academic societies, as well as for post-marketing surveys.

Astroscale <186A>: 821 yen (-7 yen)

A reversal occurred. The subsidiary Astroscale announced that it successfully approached a distance of about 15 meters from the target debris in the mission of the commercial debris removal demonstration satellite "ADRAS-J," which started in February. This approach was independently conducted by the operator as part of a private mission, separate from the mission requirements of the Japan Aerospace Exploration Agency (JAXA), marking it as the closest distance a private company has approached actual debris through RPO (Rendezvous and Proximity Operations) in the world. However, caution around tomorrow's Earnings Reports has led to a situation where buying was dominant initially but selling is now prevailing.

GA TECH <3491>: 1238 yen (-27 yen)

Decline. Announced the results for the fiscal year ending October 2024. Sales revenue amounted to 189.883 billion yen (an increase of 29.5% year-on-year), operating profit reached 4.056 billion yen (an increase of 86.6% year-on-year), and the profit attributable to shareholders was 1.841 billion yen (an increase of 82.2% year-on-year), indicating substantial increases in both revenue and profit. The flow business is aiming for expansion through improvement of commission fees and diversification of the product lineup, while transitioning to a robust revenue structure through the accumulation of stable income from stock business, and expects double-digit growth in revenue and profit for the fiscal year ending October 2025. However, initial buying was suppressed by selling pressure, resulting in a decline.